Showing 561-570 of 2366 results for "".
Update on Refractory Status Epilepticus
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/update-on-refractory-status-epilepticus/30758/The first priority for the consulting neurologist is confirming the diagnosis. Treating any underlying disease does far more to improve outcome than mere suppression of seizures. Treatment options exist for prolonged SE, but clinicians must be realistic with families.Onabotulinumtoxin A for Headache: An Update
https://practicalneurology.com/diseases-diagnoses/headache-pain/onabotulinumtoxin-a-for-headache-an-update/30783/A year after FDA approval, a specialist offers an update on neurotoxin therapy for migraine and headache.Sexual Discomfort: Dealing with Dysfunction in MS and Other Neurological Conditions
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0509_01-php/30915/Sexual dysfunction can be detrimental to patients with neurodegenerative disease—especially MS. So why aren't patients—and neurologists—talking more about it?Board Re-Certification: Reform or Reboot
https://practicalneurology.com/columns/practice-management/board-re-certification-reform-or-reboot/30542/A neurologist has been leading the charge to reform MOC in neurology. He talked to Practical Neurology® about the issue.Hemicrania Continua: A Question and Answer Review
https://practicalneurology.com/diseases-diagnoses/headache-pain/hemicrania-continua-a-question-and-answer-review/30785/A headache specialist explores the incidence, diagnosis, and treatment of this frequently misdiagnosed headache type.Spinal Cord Infarct: Clinical & Imaging Pearls
https://practicalneurology.com/diseases-diagnoses/imaging-testing/spinal-cord-infarct-clinical--imaging-pearls/30394/Rising Drug Prices and the Cost of Care: What Can Physicians Do?
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/rising-drug-prices-and-the-cost-of-care-what-can-physicians-do/30327/The multiple sclerosis drug market offers a snapshot of a growing problem. Physicians should speak out on behalf of the specialty and their patients.Preferred Treatment: The Changing Economics of Multiple Sclerosis Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/preferred-treatment-the-changing-economics-of-multiple-sclerosis-care/30486/By deciding which drugs are “preferred,” insurance companies are reducing the practice of evidence-based medicine to a series of economic choices.NeuroAdvocacy: Why Lobbying Matters
https://practicalneurology.com/columns/practice-management/neuroadvocacy-why-lobbying-matters/30328/Advocating for patients and the specialty is a powerful way for physicians to make their voices heard.Confronting the Clinical Challenges of Frontotemporal Dementia
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/confronting-the-clinical-challenges-of-frontotemporal-dementia/30848/A look at FTD's symptoms, pathophysiology, subtypes, as well as the latest from imaging studies.